Navigation Links
TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
Date:5/1/2009

ease contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


                                  (Tables Follow)

                          TorreyPines Therapeutics, Inc.
                      Condensed Consolidated Balance Sheets

                                   (in thousands)

                                                      March 31,  December 31,
                                                        2009        2008
                                                     (Unaudited)
    Assets
    Current assets
      Cash and cash equivalents                        $6,319     $10,864
      Prepaid expenses and other current assets           379         187
      Total current assets                              6,698      11,051

    Long-term assets                                       11          79

    Total assets                                       $6,709     $11,130

    Liabilities and stockholders' equity
    Current liabilities                         
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 BCC Research ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS ... (PCR) technology reached nearly $140 billion in 2013. This ... registering a five-year compound annual growth rate (CAGR) of ... number of interesting and exciting possibilities within the broader ...
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... EMERYVILLE, Calif. , May 4 S*BIO Pte Ltd and ... their development collaboration and option and license commercialization agreement for S*BIO,s novel ... 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration ... , , ...
... 4 Romark Laboratories announced results from its STEALTH C-3 ... patients with genotype 1 chronic hepatitis C.  Study results were presented ... of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease ... , , ...
... ... Sepha , is challenging traditional thinking on leak testing procedures through ... its new leak-testing technology can increase competiveness and revolutionise current packaging test methods within ... ...
Cached Biology Technology:S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3
(Date:7/11/2014)... evidence has demonstrated that transplantation of mesenchymal stem cells ... or mouse models of Alzheimer,s disease (AD) and improve ... ischemia. Few studies are reported on the therapeutic effect ... AD and on the effect on oxidative injury and ... Yan and her team, School of Life Sciences, Tsinghua ...
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
(Date:7/11/2014)... In the brains of all vertebrates, information is ... electric or chemical signal to be passed from ... are the most abundant type of synapse, can ... crucial for learning, memory, perception and cognition, and ... for brain function. For instance, every time ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2
... U.S. agricultural practices create 58 percent of nitrous oxide ... gas in the atmosphere. Scientists believe nitrous oxide contributes to ... practices and products have been introduced to address this issue, ... to experiment with ideas that may ultimately hurt the "bottom ...
... considered overweight and more than one-third categorized as obese, ... is a major national goal. Mathematical modeling of the ... growing subfield of obesity research, which can be used ... Mathematical and Biological Synthesis (NIMBioS) is now accepting applications ...
... available in German . , "Don,t be a frog!" ... away. However to be called a frog should actually be a ... at least from the point of view of evolutionary biology: ... are superior to all the other amphibians, and even mammals", says ...
Cached Biology News:MU scientists find new farming method to reduce greenhouse gases, increase farm yields 2Body weight regulation and metabolism focus of workshop 2Inventions of evolution: What gives frogs a face 2
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: